A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Name: A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
Published: 2013
License: Public Domain

Janssen Research & Development, LLC · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

ulcerative-colitis

colitis, ulcerative, ulcerative colitis, moderately to severely active ulcerative colitis, golimumab, simponi, human anti-tnfα antibody, pediatric participants, safety and pharmacokinetics, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Related documents